Company ProfilePremium

Perfect Medical Health Management Limited (formerly Perfect Shape Medical Limited)

Company Profile Analysis

Ticker: 1830.HK完美醫療健康管理有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Perfect Medical Health Management Limited - Company showcase

Year Founded & Workforce

2003

787 Employees

Perfect Medical Health Management Limited logo

Perfect Medical Health Management Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Perfect Medical Health Management Limited Overview

Perfect Medical is a founder-controlled, Hong Kong-centred operator of non-invasive aesthetic medical centres. Around its core aesthetic medical business it has built a set of non-aesthetic "health management" services: hair growth, pain management, snoring treatment, and Japanese-style sleep therapy under the "Goku Spa" brand.

Hong Kong generates about 80% of revenue. The rest comes from Mainland China (Beijing, Shanghai, Guangzhou, Shenzhen), Macau, Australia (Sydney, Melbourne) and Singapore.

The business model is cash-rich and asset-light. Customers prepay treatment packages, the company carries no bank debt, and it has paid out 100% or more of its profits as dividends for eleven consecutive years.

Revenue peaked at HK$1.39bn in FY2023–FY2024. It has since fallen 31% as Hong Kong consumers shifted spending to Shenzhen and South Korea. Management has responded by consolidating stores, cutting headcount by 38% from FY2023 to FY2026, deploying AI-driven marketing, and pursuing a multi-brand strategy that includes the Korean dermatology brand "Oracle".


Company's own description

The annual report describes the company itself as an investment holding company. Its subsidiaries provide medical and aesthetic medical services. [S1]

The FY2025/26 report sets out a mission with four parts:

  • the best customer service and experience;

  • maximum returns for shareholders;

  • empowering employees;

  • social responsibility.

It also names five pillars under the banner of maintaining sustainable growth:

  • (i) aesthetic and non-aesthetic service offerings (pain management, hair growth, sleep therapy);

  • (ii) high value-for-money Korean medical beauty services;

  • (iii) cross-selling within an ecosystem;

  • (iv) AI-driven marketing;

  • (v) operational efficiency and cost control. [S1]

Management describes "4 major business sectors": Aesthetic Medical, Hair Growth, Pain Management and Sleep Therapy. [S2, S3]

Independent characterisation

MetricFY2023FY2024FY2025FY2026
Avg spending per client, aesthetic medical (HK$)28,02628,784——
Avg spending per client, non-aesthetic medical (HK$)14,37815,666——
Avg customer spending excl. promotional packages, alternative definition (HK$)—54,00047,000—
Aesthetic medical share of sales contracts (%)—81.8——
Total leased service area ('000 sq ft)—304279243

Economically, Perfect Medical is a prepaid consumer-services retailer with a medical licence wrapper.

How revenue is earned: Customers sign "sales contracts" for treatment packages, usually prepaid and sometimes paid by instalment or credit card. The company holds this cash and recognises revenue as treatments are delivered. Sales contracts were HK$1,446.4m in FY2024, against revenue of HK$1,393.3m. [S3]

What drives margins: The main levers are therapist utilisation, rent per square foot, and marketing cost per customer acquired.

Payment arrangements: Some credit-card and instalment facilities are secured by pledged bank deposits. [S1]

Revenue model mix. About 100% of revenue is service-based (treatments). Product sales have been a minor complement since 2004. There is no material subscription or licensing income. Membership and package prepayment work in a similar way to a subscription, but are recognised on delivery.

Value chain position. The company is a downstream, self-operated service provider. It buys equipment and consumables from device and consumable vendors. Supplier concentration is high: in FY2026 the top five suppliers accounted for 78.81% of purchases and the largest single supplier for 57.23%. [S1]

Customers. The customer base is retail consumers, mostly women, in the mid-to-high-end bracket. Customer concentration is negligible: the top five customers were 0.92% of FY2026 sales. [S1] The workforce is also predominantly female, with a women-to-men ratio of 716:71 at 31 March 2026. [S1]

End-markets served:

  • non-invasive medical aesthetics (energy-based devices, injectables, skin treatments);

  • hair-loss treatment;

  • musculoskeletal pain management;

  • sleep and stress therapy;

  • snoring treatment;

  • Korean-style dermatology (via "Oracle").

Key operating metrics disclosed

Sources: [S1, S2, S3]. The two average-spend series use different definitions. The FY2025 AR's HK$54,000 figure for FY2024 does not reconcile with the FY2024 AR's HK$28,784. No average-spend metric was disclosed for FY2026. The FY2026 total service area is derived from 145,000 sq ft in Hong Kong plus 98,000 sq ft outside Hong Kong.

Strategy

Stated strategic themes (paraphrased from AR FY2025/26 and AR FY2024/25)

  1. Premiumisation over price competition. Protect margins through brand equity and customer experience rather than discounting. [S1]

  2. Multi-brand ecosystem. Strengthen "Perfect Medical" and "New Beauty", and scale high-potential concepts such as Oracle and Goku Spa to reach different demographics. [S1]

  3. Non-aesthetic services as entry points. Use pain, hair, sleep and snoring services as low-friction acquisition channels that cross-sell into higher-margin aesthetics. [S1]

  4. AI and digital transformation. Apply AI across marketing, CRM and operations to lower customer acquisition cost, raise retention and automate administration. [S1, S2]

  5. Network optimisation. A two-phase plan: rightsizing in H1 FY2026, then stabilisation and same-store productivity. [S1]

  6. Financial discipline and shareholder returns. Zero bank debt and a sustainable dividend policy. The formal policy has no fixed payout ratio, but the track record is 100% or more for 11 years. [S1]

  7. Geographic posture.

    • Hong Kong: core.

    • PRC: defensive and focused on premium cities.

    • Australia and Singapore: optimise for cash flow. [S1]

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeTimingStatus / target
Cost-optimisation programme: headcount, lease renegotiations, store consolidationH2 FY2025 – H1 FY2026Headcount cut by 302 against the FY2024 baseline (FY2025), then to 787 (FY2026). Key costs down 15.4% in FY2026. [S1, S2]
Oracle exclusive HK cooperation (Korean dermatology)Signed Q1 FY2026Rolled out in FY2026; management says it reached younger clients. No revenue disclosed. [S1]
Goku Spa PRC expansionH2 FY2025Entered South and East China; losses narrowing (FY2025). [S2]
Shenzhen clinic M&A pipelineAnnounced in AR FY2025 (June 2025)Seeking high-potential medical beauty clinics in Shenzhen to capture cross-border demand. No acquisition completed as of AR FY2026. [S1, S2]
AI-driven marketing and CRMFY2024 onwardMarketing spend down 16.5% in FY2026 while sales momentum improved in H2. [S1]
Value-driven packages and flexible instalment plansFY2026Deployed to defend traffic. [S1]
Snoring treatment launchFY2026Operational. [S1]
2026 Share Option Scheme and 50m-option grant to CEOApr–Jun 2026Approved 18 June 2026. [S1]
ESG: green depositsFY2023–FY2024HK$214.0m (FY2023) and HK$265.9m (FY2024) placed in bank green deposits. [S3, S4]

Medium-term targets and guidance

No quantitative medium-term targets: (revenue, margin or store count) have been published.

  • Qualitative guidance (AR FY2026, 30 June 2026):

    • momentum continued into early FY2027, with "encouraging" April and May 2026;

    • measured growth;

    • selective multi-brand expansion;

    • exploring strategic opportunities. [S1]

  • AR FY2025 said the Oracle plus Shenzhen M&A "dual-track" strategy would underpin profit growth "over the next five years", without numbers. [S2]

Products & Services

Pricing is package-based and is not publicly disclosed at list-price level. The only available proxies are average spending per client.

Aesthetic medical (core; about 82% of sales contracts in FY2024)

Offering / brandDescriptionTarget customerLaunch / latestNotes
Perfect Medical (flagship brand)Non-invasive medical aesthetics delivered in flagship "mega centres" and residential shops: energy-based device treatments for skin rejuvenation, tightening and body contouring, and injectables. Specific devices are not itemised in the reviewed sources.Mid-to-high-end HK and cross-border clientsBrand since 2021 rename; flagship model since 2013Flagships in Mong Kok (Langham Place), Causeway Bay, Tsim Sha Tsui, Admiralty [S2, S3]
New BeautyA second core brand named in the FY2026 outlook as a flagship alongside "Perfect Medical". Its specific positioning is not described.——[S1]
Oracle (exclusive HK partnership)A premium Korean medical beauty concept led by dermatologists, with Korean fashion-style elements, positioned as high value-for-money.Younger demographic; value-seeking clients who might otherwise travel to KoreaAgreement Q1 FY2026; rollout during FY2026Management says it broadened the customer base to younger clients [S1, S2]
Dr Face (historical)Earlier medical beauty brand: injectables (Botox, Restylane, Sculptra) and lasers (hair removal, rejuvenation, depigmentation)Not applicablePre-2021—
Perfect Shape 必瘦站 (legacy)Original slimming and beauty brandNot applicable2,003Replaced by Perfect Medical branding in 2021 [S7, S9]

Non-aesthetic medical / health management

OfferingDescriptionLaunchNotes
Pain managementSpecialist pain-treatment medical centres combined with aestheticsFirst centre 30 Nov 2020A model branch generated HK$44.8m of contracts in 60 business days [S18]
Hair growthHair-loss and regrowth treatment programmesAround FY2021–FY2022One of the "4 major business sectors" [S3]
Goku Spa (sleep therapy)Japanese head-therapy techniques aimed at stress, anxiety and poor sleep. Run as a JV/cooperation with a Japanese luxury brand.Jan 2024 (HK, 7 locations by Mar 2024); South and East China entry in H2 FY2025Loss-making in FY2025, with losses "narrowing significantly" [S2, S3]
Snoring treatmentSpecialised treatment lineFirst named in AR FY2026Described as a low-friction entry point for new members [S1]
Product salesSkincare and slimming products complementing servicesSince 2004Immaterial [S9]

Store formats

FormatDescriptionSince
Flagship / mega centreLarge multi-service hubs that centralise personnel and equipment2013 [S3]
Residential shopSmaller, lower-capex neighbourhood shops feeding flagship centres ("Dual-Circulation")June 2023 [S3]
Concept storeDevice-focused stores. Each reportedly cost about HK$5–6m in capex and broke even in about 6 weeks (from a chairman interview).Yuen Long, Taikoo Shing [S18]

Financial Narrative

Income statement — chartable

Sources: [S1–S5]. Gross profit is not reported, because the company presents expenses by nature. One aggregator shows FY2025 "gross profit" of HK$701.2m (62.2%) on its own definition [S12]; this is not a company figure.

Margins — chartable

FY2022 EBITDA and operating margins are derived; the other figures are company-reported. [S1–S5]

Revenue CAGR (derived):

  • FY2022→FY2026: −8.1% a year.

  • FY2020 (HK$1,241.0m)→FY2026: −4.2% a year.

  • FY2012 (HK$381.2m)→FY2026: +6.8% a year. [S3, S9]

Longer history (context) — chartable

Sources: [S2, S3, S6]

Cost structure — chartable

Sources: [S1, S2, S3]. FY2025 figures are as restated in AR FY2026. Percentages are derived.

Balance sheet — chartable

Sources: [S1–S5]. The FY2022 cash figure is "cash and cash equivalents". Financial investments are those listed in the MD&A "significant investments" table: listed equities, plus from FY2026 US ETFs and bank unit trusts. FY2026 total = HK$80.3m listed equities + HK$77.9m ETFs + HK$70.2m unit trusts.

Cash flow — chartable

Sources: [S1–S5]. FCF and dividends declared are derived.

Share capital fell slightly from HK$125.653m (FY2023) to HK$125.619m (FY2024), which implies a small repurchase of about 0.34m shares in FY2024. Its value was not disclosed in the reviewed sources.

Ratios — chartable

Sources: [S1–S5]. FY2022 ROE is derived; the FY2022 ROA of 23.8% is as reported in AR 2023. Total liabilities/equity, asset turnover and net debt/EBITDA are derived. The FY2022 current ratio was below 1.0, as the company reported net current liabilities of HK$14.8m.

The following were not disclosed:

ROIC: It is not meaningful on standard definitions, because invested capital ex-cash is close to zero or negative (deferred revenue funds working capital).

Cash conversion cycle: It is not meaningful for a prepaid-services model.

Commentary on trends, inflections and drivers

Plateau (FY2022–FY2024).

  • Revenue stalled at about HK$1.35–1.39bn after the FY2022 post-COVID rebound (+23.9%).

  • FY2023 profit included one-off HK government Employment Support Scheme subsidies. Excluding them, FY2024 profit grew 6.8%. [S3]

  • Margins were stable: net margin about 22.6–22.7%.

  • Dividends ran ahead of earnings (payouts of 118.6% and 125.5%), which drew down cash from HK$656.8m to HK$575.3m.

Inflection (FY2025).

  • Revenue fell 19.1% and profit fell 34.5%.

  • Management blamed weak HK consumer confidence and HK residents seeking cheaper aesthetic treatments in Shenzhen and South Korea. HK retail sales fell 7.3% in 2024. [S2]

  • Fixed costs (staff and rent) did not flex fast enough, so EBITDA margin fell almost 5 percentage points to 28.3%.

  • The worst half was H2 FY2025, with a net margin of 13.0%.

Rightsizing (FY2026).

  • Headcount fell from 971 to 787 (−19%; −40% from 1,317 at FY2023).

  • Leased area fell from 279k to 243k sq ft.

  • Marketing spend fell 16.5% and rent-related costs fell 10.8%.

  • Total key costs fell 15.4%, slightly more than the 14.7% revenue decline, so operating margin held at 22.1% and net margin improved to 18.6%.

Structural observations.

  1. The business generates exceptional ROE (46–64%), because equity is deliberately kept small through more-than-100% payouts and customer prepayments fund working capital.

  2. The equity base has stopped shrinking (HK$387.9m in FY2026 against HK$378.7m in FY2025), but cash keeps falling. Some cash has been redeployed into a HK$228m investment portfolio that now includes US tech stocks and ETFs. This raises capital-allocation questions.

  3. The working-capital cushion has thinned. Net current assets fell from HK$231.5m (FY2023) to HK$20.1m (FY2026), and the current ratio from 1.44x to 1.06x. Continued over-100% payouts will be harder to sustain without earnings growth.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

Hong Kong revenue (HKD Mn)

975.11,040.11,081.4893.8765.6

Outside Hong Kong revenue (HKD Mn)

374.9349.2311.9234.1196.8

Total revenue (HKD Mn)

1,350.01,389.31,393.31,127.9962.3

Hong Kong share of revenue (%)

72.274.977.679.279.6

Outside HK share of revenue (%)

27.825.122.420.820.4

Hong Kong revenue YoY growth (%)

—6.74.0-17.3-14.3

Outside HK revenue YoY growth (%)

—-6.9-10.7-24.9-15.9

Revenue by Segment and Segment Margins & Growth (%)

MetricH1FY2023H2FY2023H1FY2024H2FY2024H1FY2025H2FY2025H1FY2026H2FY2026

Revenue (HKD Mn)

668.3721.0718.1675.2620.3507.6485.9476.4

Profit attributable (HKD Mn)

150.7164.9166.4149.4140.866.094.883.9

Net margin (%)

22.522.923.222.122.713.019.517.6

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

1,350.01,389.31,393.31,127.9962.3

Revenue YoY growth (%)

23.92.90.3-19.1-14.7

EBITDA, company definition (HKD Mn)

469.5482.3461.3319.1268.5

Operating profit (HKD Mn)

392.5396.1382.4251.6213.0

Profit before tax (HKD Mn)

—391.5383.7252.5211.2

Profit attributable to equity holders (HKD Mn)

305.2315.6315.8206.9178.7

EPS basic (HK cents)

24.825.325.116.514.2

EPS diluted (HK cents)

24.825.325.116.514.2

Dividend per share, total (HK cents)

24.830.031.516.614.6

Dividend payout ratio (%)

100.0118.6125.5100.6102.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin (%)

34.834.733.128.327.9

Operating margin (%)

29.128.527.422.322.1

Net margin (%)

22.622.722.718.318.6

Income Statement and Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

1,241.01,089.81,350.01,389.31,393.31,127.9962.3

Operating profit (HKD Mn)

456.2365.9392.5396.1382.4251.6213.0

Profit attributable (HKD Mn)

360.2284.6305.2315.6315.8206.9178.7

EPS basic (HK cents)

32.224.324.825.325.116.514.2

DPS total (HK cents)

34.038.024.830.031.516.614.6

Income Statement

MetricFY2023FY2024FY2025FY2026

Cost of inventories & consumables (HKD Mn)

32.527.617.821.0

Employee benefit expenses (HKD Mn)

470.6471.7408.9333.7

Marketing expenses (HKD Mn)

150.8159.6140.3117.2

Depreciation of PP&E (HKD Mn)

86.378.967.555.5

Rental lease related expenses (HKD Mn)

174.0165.1147.9132.0

Other operating expenses (HKD Mn)

118.8126.2108.594.7

Total key costs (HKD Mn)

1,033.01,029.0890.9754.0

Employee costs as % of revenue

33.933.936.334.7

Rent-related costs as % of revenue

12.511.813.113.7

Marketing as % of revenue

10.911.512.412.2

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD Mn)

1,281.21,296.31,221.8935.9834.2

Total liabilities (HKD Mn)

786.9684.0725.0557.2446.3

Total equity (HKD Mn)

494.3612.3496.8378.7387.9

Cash & bank balances (HKD Mn)

444.6656.8575.3394.6294.9

Bank borrowings (HKD Mn)

00000

Net debt excl. leases (HKD Mn)

-444.6-656.8-575.3-394.6-294.9

Net current assets (HKD Mn)

-14.8231.5180.372.420.1

Financial investments at fair value (HKD Mn)

—81.059.795.5228.4

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Net cash from operating activities (HKD Mn)

513.9560.6497.1332.9339.5

Capital expenditure (HKD Mn)

——50.133.524.6

Free cash flow, OCF minus capex (HKD Mn)

——447.0299.4314.9

Dividends declared, derived DPS x shares (HKD Mn)

307377396209183

Share buybacks (HKD Mn)

———00

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE, company (%)

61.851.663.654.545.9

ROA, company (%)

23.824.325.822.121.4

Current ratio (x)

—1.441.351.181.06

Bank debt / equity (x)

00000

Total liabilities / equity (x)

1.591.121.461.471.15

Asset turnover, revenue / total assets (x)

1.051.071.141.211.15

Net debt / EBITDA excl. leases (x)

-0.95-1.36-1.25-1.24-1.10

Revenue by Region and Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025FY2026

Hong Kong (HKD Mn)

975.11,040.11,081.4893.8765.6

Mainland China + Macau + Australia + Singapore (HKD Mn)

374.9349.2311.9234.1196.8

Hong Kong YoY growth (%)

—6.74.0-17.3-14.3

Outside HK YoY growth (%)

—-6.9-10.7-24.9-15.9

Revenue by Region

RegionH1FY2023H1FY2024H1FY2026

Hong Kong revenue (HKD Mn)

492.4549.6386.8

Outside HK revenue (HKD Mn)

175.9168.599.0

Share Price & Returns

PeriodReturn (%)Start price (HKD)

3 months

15.651.15

Year to date 2026

7.261.24

1 year

-15.291.57

3 years

-65.903.90

5 years

-79.736.56

Since IPO (adjusted)

530.450.21

Valuation Multiples

MultiplePerfect MedicalBasis

Market cap (HKD Mn)

1,671

1,256.2m shares x HK$1.33

P/E (x)

9.4

1.33 / 0.142

Dividend yield (%)

11.0

14.6c / HK$1.33

P/B (x)

4.3

1,671 / 387.9

EV, ex-leases, net of cash and investments (HKD Mn)

1,148

1,671 − 294.9 − 228.4

EV/EBITDA (x)

4.3

Company post-rent EBITDA of 268.5

EV/Sales (x)

1.19

Revenue 962.3

EC Healthcare P/S (x), peer

0.12

Market cap about 450 / revenue 3,770.2

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Interim DPS (HK cents)

17.713.013.211.27.6

Special DPS, all specials in year (HK cents)

04.76.40.10

Final DPS (HK cents)

7.112.311.95.37.0

Total DPS (HK cents)

24.830.031.516.614.6

Payout ratio (%)

100.0118.6125.5100.6102.8

Analyst Conclusions

Management guidance

There is no numerical guidance. The FY2026 annual report says:

  • recovery momentum continued, with "encouraging" April and May 2026;

  • the focus is on core Hong Kong services, selective multi-brand expansion and strategic opportunities;

  • cost discipline and a sustainable dividend policy will be maintained. [S1]

Bull case

  1. Operating leverage on recovery. Costs have been reset: headcount −40% and leased area −20% since FY2024. If revenue simply stabilises at the H2 FY2026 run-rate of about HK$476m per half and grows modestly, the H2 FY2026 net margin of 17.6% could move back towards the historical 22–23%.

  2. Valuation and yield. At about 9.4x P/E, 4.3x post-rent EV/EBITDA and an 11% yield, with HK$523m of cash and investments (about 31% of market cap), the market prices in continued decline. The largest listed HK peer, by contrast, is loss-making.

  3. Competitive shake-out. Smaller operators are exiting, and EC Healthcare is losing money while Perfect Medical stays profitable. Oracle directly targets the Korea leakage.

Bear case

  1. The leakage is structural. Revenue has fallen for two years, and outside-HK revenue for five. Shenzhen and Korean price points may cap Hong Kong pricing permanently.

  2. Dividends exceed lease-adjusted cash generation. Cash fell from HK$656.8m to HK$294.9m over three years. The current ratio is now 1.06x and net current assets only HK$20.1m. A sub-100% payout or a dividend cut would remove the main support for the shares.

  3. Governance and capital allocation. The company has 75% family control and a combined Chair/CEO. It granted a 50m-option award to the controller at the share-price trough. HK$228m (27% of total assets) is held in equities and ETFs rather than returned to shareholders or invested in the business. Minority shareholders bear these risks.

Catalysts and monitorables (next 12 months)

H1 FY2027 interim results (expected late Nov 2026): HK year-on-year revenue trend; interim DPS against EPS; cash balance.

Oracle: contribution and any disclosure of new-customer metrics.

Shenzhen M&A: execution, price and structure.

  • Exercise of the 50m-option grant, and any further option schemes.

HK retail sales data: and outbound-travel statistics.

Supplier concentration: trend; any regulatory developments in HK or PRC aesthetics.

Investment-portfolio: marks and any reallocation.

Analyst verdict

Perfect Medical is a high-quality operator in a structurally challenged market.

On the evidence of FY2026, management can defend profitability under pressure. Revenue fell 14.7%, yet operating margin held at 22.1% and net margin improved to 18.6%. Over the same year, Hong Kong's largest listed peer lost more than HK$400m. The prepaid, debt-free model still converts profit into operating cash efficiently: OCF of HK$339.5m against net profit of HK$178.7m. Eleven consecutive years of 100%-plus payouts give the shares an unusual income profile, with a dividend yield of about 11%.

The investment case is not simply "cheap and profitable", however. The top line has fallen 31% from its peak because Hong Kong consumers have discovered cheaper substitutes across the border and in Korea. The company's own disclosures frame this as the "new normal". International expansion has repeatedly failed to diversify the business. The liquidity cushion that let the group over-distribute has shrunk:

  • cash is down 55% in three years;

  • the current ratio is 1.06x;

  • the current dividend therefore depends on earnings stabilising, not on the balance sheet.

Governance features further limit what minority investors can capture of the value: a combined Chair/CEO, family control, long-tenured INEDs, performance-free options and a sizeable discretionary equity portfolio.

Balance of evidence. The second-half FY2026 data points (year-on-year profit up 27.1%, revenue decline narrowing to 6.1%, closures halted) suggest the trough has passed. The modest multiple already discounts a lot.

Key test. The H1 FY2027 interim result needs to show stable Hong Kong revenue and an interim dividend covered by earnings without further cash drawdown. If it does, a re-rating towards 11–12x earnings is plausible. If it does not, the yield is at risk of being cut, and the low multiple would prove to be a value trap rather than an opportunity.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (AR 2026)Background

Dr. Au-Yeung Kong

Founder; Chairman & CEO; executive director; Nomination Committee member

11 Mar 2011 (founded group 2003)

54

MBBS, CUHK (1995); registered medical practitioner in HK. Brother of the two other family directors.

Ms. Au-Yeung Wai

Executive director (oversees daily operations; described as COO by aggregators); Nomination Committee member

11 Mar 2011 (joined 2004)

57

BA Accountancy, CityU (1991); master's in business studies, University of Kent (1995)

Ms. Au-Yeung Hung

Executive director (operational management of service centres)

11 Mar 2011 (joined 2005)

62

BBA, University of Southern Queensland (1992)

Mr. So Hin Lung

Executive director; CFO; Company Secretary

ED 28 Sep 2022 (joined Mar 2011)

49

Former Deloitte audit manager; EMBA, CUHK; MCF, PolyU; HKICPA member

Ms. Hsu Wai Man, Helen

INED; Audit Committee chair

5 Dec 2011

56

Former Ernst & Young partner (18 years); FCPA (HK), AICPA. INED of several other listcos.

Mr. Chi Chi Hung, Kenneth

INED; Remuneration Committee chair

5 Dec 2011

57

30+ years in accounting and finance; FCCA

Ms. Cho Yi Ping

INED; Nomination Committee chair

14 Aug 2015

48

Solicitor; partner at Wong & Tang Solicitors; LLB, HKU

Mr. Chuk Sai Cheong Simon

INED

1 Jul 2024

44

Partner, Templewater (APAC mid-market buyouts); about 20 years in PE and investment banking; Columbia BA

Governance Detail

Data pointDetailSource

FY2026 key-management pay bands (8 people)

4 at nil–HK$1m; 3 at HK$1–5m; 1 over HK$5m

S1

—

Dr. Au-Yeung Kong HK$31.56m; Ms. Au-Yeung Wai HK$4.97m; Ms. Au-Yeung Hung HK$4.97m; Mr. So HK$0.92m

S15

Options granted 12 Dec 2023

1.256m each to the three family directors at HK$3.346; no performance targets

S3

Options granted 7 Jan 2025

1.256m each to the three family directors at HK$2.208; no performance targets

S2

Conditional grant (approved 18 Jun 2026)

50,000,000 options to Dr. Au-Yeung Kong at HK$1.184 under the 2026 Share Option Scheme, about 4.0% of issued shares

S1

Board & Management Changes

DateChange

28 Sep 2022

CFO So Hin Lung appointed executive director

1 Jul 2024

Chuk Sai Cheong Simon appointed INED (fourth INED, to refresh long-tenured independence)

28 Sep 2025

So Hin Lung's new 3-year service contract begins

23 Apr 2026

Executive directors exit the Remuneration Committee

18 Jun 2026

2021 option scheme terminated; 2026 scheme adopted

Major Shareholders

HolderShares% of issuedDateSource

Dr. Au-Yeung Kong (direct, 114,834,747 shares, plus deemed interest via Sure Sino)

942,003,768 plus options

75.18 (incl. options)

31 Mar 2025

S2

Sure Sino Investments Ltd (family holding company), total

827,169,02165.85

31 Mar 2024

S3

— of which held directly by Sure Sino

459,739,48136.60

31 Mar 2024

S3

— of which Earlson Holdings Ltd

208,306,51116.58

31 Mar 2024

S3

— of which Perfect Medical Charity Foundation Ltd

159,123,02912.67

31 Mar 2024

S3

Mr. So Hin Lung

140,0000.01

31 Mar 2025

S2

Free float (derived)

about 314m

about 25

2025

derived

Competitive Landscape

Key Competitors

CompetitorSegment overlapListingLatest revenuePositioning vs Perfect Medical

EC Healthcare (醫思健康; formerly Union Medical Healthcare)

HK aesthetic medical, beauty and wellness; also medical, dental, veterinary

HKEX 2138

FY2026 HK$3,770.2m total; aesthetic, beauty and wellness HK$1,322.9m; loss HK$412.9m [S17]

Larger, diversified, loss-making. Perfect Medical is far more profitable, but EC Healthcare's aesthetic segment alone is about 1.4x Perfect Medical's total revenue.

DR REBORN (brand)

HK medical aesthetics chain

——

Direct HK chain competitor

Beauty Farm Medical and Health Industry

PRC beauty and wellness chain

HKEX 2373

—

Competes in PRC beauty and wellness

So-Young International

PRC medical aesthetics platform and clinics

NASDAQ SY

—

Online channel and clinic competitor in the PRC

Shenzhen medical aesthetic clinics (fragmented)

Cross-border substitutes for HK clients

Mostly private

Not applicable

Main source of share loss in FY2025–FY2026 [S1, S2]

South Korean dermatology clinic chains (Seoul)

Medical tourism substitute

Private

Not applicable

Main source of share loss; Oracle partnership is the response [S2]

Neo Derm (HK)

HK medical aesthetics

——

HK mid-to-high-end competitor

Modern Beauty Salon (HK)

HK beauty services

——

Traditional beauty competitor

Independent HK dermatology and aesthetic clinics

Doctor-led injectables and lasers

Private

Not applicable

Fragmented competition. Management notes smaller operators exiting the market in FY2026 [S1].

Australian and Singapore aesthetic chains

Local markets

Various

Not applicable

Local competitors in sub-scale overseas operations

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricPerfect Medical (FY2026)EC Healthcare (FY2026)

Revenue (HKD Mn)

962.33,770.2

Revenue growth (%)

-14.7-8.9

Net margin (%)

18.6-11.0

Operating / EBITDA margin (%)

22.1 / 27.9

—

Market cap (HKD Mn, about Aug 2026)

about 1650

about 450

Company Snapshot

$123.5M

Revenue

787

Employees

2003

Founded

Kowloon, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Exceptional profitability. Net margin was 18.6% in FY2026 against a HK$412.9m loss at EC Healthcare, the largest listed HK peer. [S1, S17]
  • Debt-free balance sheet. Zero bank borrowings in every year FY2022–FY2026; cash of HK$294.9m at 31 March 2026. [S1]
  • Self-funding model. OCF was HK$339.5m in FY2026, about 1.9x net profit, because customer prepayments fund the business. [S1]
  • Shareholder-return record. Payout of 100% or more for 11 consecutive years; more than HK$3.28bn of cumulative dividends since 2012. [S1, S2]
  • Cost flexibility. Key costs fell 15.4% in FY2026, keeping operating margin stable at 22.1% against 22.3%. [S1]
  • Founder-doctor leadership and continuity. The CEO has led since 2003 and the CFO has served since 2011. [S1]
  • Partnership agility. Goku Spa (Jan 2024) and Oracle (2025) were launched quickly on the existing membership base. [S1, S3]

Weaknesses

  • Revenue down 31% from the FY2024 peak (HK$1,393.3m to HK$962.3m). [S1, S3]
  • Geographic concentration. Hong Kong was 79.6% of revenue in FY2026. [S1]
  • Failed international scaling. Outside-HK revenue fell 52% between FY2021 and FY2026; the PRC network is far below the 44 centres at IPO. [S1, S6, S9]
  • Thin liquidity buffer. The current ratio fell to 1.06x and net current assets to HK$20.1m (FY2026). [S1]
  • Supplier concentration. The largest supplier was 57.23% of purchases. [S1]
  • Governance. Combined Chair/CEO; three family members on the board; three INEDs with more than 9 years' tenure; options granted without performance targets. [S1, S2]
  • Limited disclosure. No revenue by service line or by country; no store count. [S1]

Opportunities

  • HK consumption recovery. 12 consecutive months of retail sales growth to April 2026; early-FY2027 trading described as encouraging. [S1]
  • Market exit by smaller operators. Room for share gains, as management notes. [S1]
  • Oracle. Recapture Korea-bound spending and reach younger clients. [S1]
  • Shenzhen clinic M&A. Follow cross-border demand. Balance-sheet capacity exists, though it has not yet been executed. [S2]
  • Non-aesthetic entry services (pain, hair, sleep, snoring) to cut acquisition cost and cross-sell. [S1]
  • AI-driven CRM. Marketing costs fell 16.5% in FY2026 while H2 trading recovered, suggesting productivity gains. [S1]

Threats

  • Continued cross-border leakage to Shenzhen and Korea, which management repeatedly identifies as the core headwind. [S1, S2]
  • PRC regulatory tightening and consumption downgrade. [S1]
  • Regulatory risk in HK aesthetics. The annual report notes that non-compliance could lead to penalties or suspension. [S1]
  • Dividend sustainability. The 102.8% FY2026 payout came with falling cash. A dividend cut would remove the main valuation support.
  • Market risk on the investment portfolio. HK$228.4m, 27% of total assets, sits in equities and funds, including concentrated tech exposure (Tencent, NVIDIA, TSMC, Nasdaq ETFs). [S1]
  • Inflation and wage pressure in Australia and Singapore. [S2, S3]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–Jun 2025Exclusive Oracle (Korea) cooperation signed for HKFirst Korean brand; younger demographic [S1, S2]
27 Jun 2025FY2025 results: revenue −19.1% to HK$1,127.9m; profit −34.5% to HK$206.9m; EPS 16.5cFirst large earnings decline since FY2021 [S2]
27 Jun 2025Shenzhen clinic M&A strategy disclosedPotential inorganic growth; not yet executed [S2]
27 Jun 2025Cumulative dividends since listing exceed HK$3.28bnSupports the income-stock positioning [S2]
15 Jul 2025AR FY2024/25 published; FY2025 ESG report referencedDisclosure [S2]
8 Aug 2025AGM; re-election of Au-Yeung Wai, Au-Yeung Hung and three long-tenured INEDsGovernance continuity [S2]
22 Aug 2025Record date for FY2025 final dividend of 5.3c (total 16.6c, payout 100.6%)Dividend [S2]
H1 FY2026HK store consolidation: closures and mergers into flagship hubsCost base reset [S1]
28 Sep 2025CFO So Hin Lung signs a new 3-year service contractContinuity [S1]
28 Nov 2025Interim FY2026: revenue −21.7% to HK$485.9m; profit −32.7% to HK$94.8m (+43.4% half-on-half); interim dividend 7.6c (payout 101.3%)First sign of profit stabilisation [S10]
28 Nov 2025H1 FY2026 HK revenue HK$386.8m; outside HK HK$99.0mRegional detail [S10]
Late 2025Analyst downgrades EPS forecasts (per Simply Wall St); shares about HK$1.40–1.45Sentiment trough [S12]
H2 FY2026Store closures halted; HK area about 145k sq ftStabilisation [S1]
H2 FY2026AI marketing and CRM integration accelerated; marketing −16.5% for the full yearEfficiency [S1]
FY2026Charitable donation booked. Excluding it, profit fell 10.6% (margin 19.2%). The amount was not disclosed in the reviewed sources.One-off item [S11]
FY2026Treasury rotation: exits Hang Seng Bank, MTR and Meituan; adds TSMC, US ETFs (QQQ, QQQM, VOO, SPY, IVV) and bank unit trustsInvestment portfolio grows to about HK$228m (27% of total assets) [S1, S2]
FY2026 (between Jul 2025 and Jun 2026)Head office moves from 51/F to 30/F Langham Place Office TowerLikely cost saving (inference) [S1, S2]
23 Apr 2026Executive directors resign from the Remuneration CommitteeImproves governance optics [S1]
28 Apr 20262026 Share Option Scheme proposed, with a conditional 50m-option grant to the Chairman/CEO at HK$1.184About 4% potential dilution; governance flag [S1]
2 Jun 2026EGM circular issuedDisclosure [S1]
18 Jun 2026EGM approves the scheme and the conditional grant (independent shareholders); 2021 scheme terminatedIncentive realignment [S1]
29 Jun 2026Peer EC Healthcare reports an FY2026 loss of HK$412.9m on revenue −8.9%Industry stress; weaker competitor [S17]
30 Jun 2026FY2026 results: revenue HK$962.3m (−14.7%); profit HK$178.7m (−13.6%); H2 profit +27.1% year on year; final dividend 7.0c (total 14.6c, payout 102.8%)11th straight year of 100%+ payout [S1, S11]
30 Jun 2026Management reports encouraging April–May 2026 tradingPositive guidance tone [S1]
31 Mar 2026 (reported Jun 2026)Headcount 787 (from 971); cash HK$294.9m (from HK$394.6m)Leaner, but the cash cushion is shrinking [S1]
15 Jul 2026AR FY2025/26 and ESG Report 2026 publishedDisclosure [S1]
7 Aug 2026AGMGovernance [S1]
21 Aug 2026Final dividend record dateDividend [S1]
Jun–Aug 2026Shares rise about 15.7% over 3 months to HK$1.33 (31 Aug 2026)Recovery trade [S13]

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Cost of inventories & consumables fell from HKD 32.5 Mn in FY2023 to HKD 21 Mn in FY2026.
Perfect Medical Health Management Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2023FY2024FY2025FY2026
Cost of inventories & consumables32.527.617.821
Employee costs as % of revenue33.933.936.334.7
Rent-related costs as % of revenue12.511.813.113.7
Marketing as % of revenue10.911.512.412.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Perfect Medical Health Management Ltd, Annual Report 2025/2026 (FY ended 31 Mar 2026), published 15 Jul 2026. (www1.hkexnews.hk)
  2. S2Annual Report 2024/2025 (FY2025). (hkexnews.hk)
  3. S3Annual Report 2024 (FY2024). (www1.hkexnews.hk)
  4. S4FY2023 Final Results Announcement (28 Jun 2023) and ACN Newswire release: www1.hkexnews.hk · acnnewswire.com
  5. S5FY2022 Final Results Announcement (30 Jun 2022). (www1.hkexnews.hk)
  6. S6FY2021 Final Results Announcement (30 Jun 2021) and Annual Report 2021: www1.hkexnews.hk · www1.hkexnews.hk
  7. S7Announcement: change of company name, stock short name, website and logo (June 2021). (newsfile.moomoo.com)
  8. S8Poll results of EGM held 31 May 2021. (newsfile.moomoo.com)
  9. S9Perfect Shape (PRC) Holdings 2012 listing document (business section) and Annual Report 2012: hkexnews.hk · hkexnews.hk
  10. S10Bulletin Express / Tiger: FY2026 interim results summary (28 Nov 2025). (www-web.itiger.com)
  11. S11Quartr: H2 2026 earnings summary (30 Jun 2026). (quartr.com)
  12. S12Simply Wall St: 1830 coverage (2025). (simplywall.st)
  13. S13The Motley Fool: SEHK:1830 quote and returns (as of 31 Aug 2026). (fool.com)
  14. S14etnet: 1830 company information (shares, listing date, IPO price, major shareholder). (etnet.com.hk)
  15. S15Yahoo Finance: 1830.HK profile. and: finance.yahoo.com · au.finance.yahoo.com
  16. S16ACN Newswire: FY2023/24 interim results and FY2022/23 interim results: acnnewswire.com · acnnewswire.com
  17. S17EC Healthcare (2138) Annual Results FY2026 and FY2025: www1.hkexnews.hk · www1.hkexnews.hk
  18. S18uSmart / Gelonghui news on 1830 (April 2021; chairman interview). and: usmart.hk · usmart.hk
  19. S19The Bamboo Works: "Rebounding Perfect Medical finds beauty safe haven in Hong Kong." (thebambooworks.com)
  20. S20Inside Retail Asia: Perfect Shape expansion article. (insideretail.asia)

Data limitations: individual director emoluments, lease liabilities, goodwill, segment profit, country-level revenue, ISIN, institutional holder register, ESG ratings and independent market-size data were not available in the sources reviewed and are marked accordingly. No figures were estimated.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.